Reuters logo
2 months ago
BRIEF-Puma Biotechnology completes targeted enrollment in Neratinib Phase III metastatic breast cancer trial
July 6, 2017 / 8:22 PM / 2 months ago

BRIEF-Puma Biotechnology completes targeted enrollment in Neratinib Phase III metastatic breast cancer trial

July 6 (Reuters) - Puma Biotechnology Inc:

* Puma biotechnology completes targeted enrollment in neratinib phase iii metastatic breast cancer trial

* Puma biotechnology inc says company anticipates that primary analysis of pfs will be available during first half of 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below